SCHEMBL7155176

SCHEMBL7155176

O=C(O)C(CS(=O)(=O)N1CCN(c2ccc(Cl)cn2)CC1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PANK3 Q9H999 1/20 0.44
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 3/20 0.43
MAPT P10636 1/20 0.43
DRD2 P14416 4/20 0.42
DRD4 P21917 3/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CHRM1 P11229 1/20 0.41
GPR119 Q8TDV5 1/20 0.41
HTR1A P08908 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR7 P34969 1/20 0.41
DRD3 P35462 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
HSD17B10 Q99714 1/20 0.40
NAMPT P43490 1/20 0.40
MMP7 P09237 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7150571 0.91 PANK3 (0.43) PANK3ALDH1A1KDM4EMAPTDRD2
SCHEMBL7360833 0.78 MMP7 (0.46) PANK3ALDH1A1KDM4EMAPTDRD2
SCHEMBL14252793 0.77 DRD2 (0.49) PANK3ALDH1A1KDM4EMAPTDRD2
SCHEMBL4813294 0.77 DRD2 (0.42) PANK3ALDH1A1KDM4EMAPTDRD2
SCHEMBL4958636 0.75 GPR119 (0.46) PANK3ALDH1A1KDM4EMAPTDRD2
SCHEMBL6785651 0.74 EGLN1 (0.42) PANK3KMT2AGPR119MMP7
SCHEMBL6785646 0.74 EGLN1 (0.42) PANK3KMT2AGPR119MMP7
SCHEMBL14252772 0.74 MMP7 (0.49) PANK3ALDH1A1KDM4EMAPTDRD2
SCHEMBL14252796 0.74 MMP7 (0.49) PANK3ALDH1A1KDM4EMAPTDRD2
SCHEMBL4818308 0.74 MMP7 (0.60) ALDH1A1KDM4EMAPTDRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030139419-A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents ASTRAZENECA AB (SE) 2003-07-24 US disclosed
EP-1261595-A1 ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS AstraZeneca AB (SE) 2002-12-04 EP disclosed
WO-2001062751-A1 ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS ASTRAZENECA AB (SE) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139419-A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents MMP13, MMP3, MMP2 PANK3 4042/4885ALDH1A1 168/4885KDM4E 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.